Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 701–800 of 1,001
Contributions of neutrophils to resolution of mucosal inflammation
Colgan, S. P., Ehrentraut, S., Glover, L. E., Kominsky, D. J., & Campbell, E. L. (2012) · Immunologic Research · doi:10.1007/s12026-012-8350-2 · Cited by 22
Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands
Ciruela, F., Fernández‐Dueñas, V., & Jacobson, K. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.001 · Cited by 21
“These receptors have a distinguishable pharmacological profile, tissue distribution and effector coupling (Jacobson and Gao, 2006) (Table 1), and its functioning have been largely studied in the CNS (Sebasti~ao and Ribeiro, 2009).”
BackgroundSelf-citationLibrán-Pérez, M., Velasco, C., López‐Patiño, M. A., Míguez, J. M., & Soengas, J. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113291 · Cited by 20
“To assess this hypothesis, we lowered circulating FA levels in rainbow trout treating fish with SDZ WAG 994 (SDZ), a selective A1 adenosine receptor agonist that inhibits lipolysis [26].”
MethodNaranjo, A. N., Chevalier, A., Cousins, G. D., Ayettey, E., McCusker, E. C., Wenk, C., & Robinson, A. S. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.11.010 · Cited by 19
“This subfamily is one of the main targets for the treatment of neurodegenerative diseases, diabetes, cancer and heart disease [2].”
BackgroundAcurio, J., Troncoso, F., Bertoglia, P., Salomón, C., Aguayo, C. R., Sobrevía, L., & Escudero, C. (2014) · BioMed Research International · doi:10.1155/2014/274507 · Cited by 21
“Four types of AR have been identified: A 1 AR, A 2AAR, A2BAR, andA3AR [16, 17].”
BackgroundAsano, T., Tanaka, K., Tada, A., Shimamura, H., Tanaka, R., Maruoka, H., Takenaga, M., & Mizushima, T. (2017) · Scientific Reports · doi:10.1038/srep40214 · Cited by 20
Ben, D. D., Antonioli, L., Lambertucci, C., Fornai, M., Blandizzi, C., & Volpini, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00212 · Cited by 20
“Medicinal chemistry efforts were aimed at developing compounds presenting higher metabolic stability and improved potency and selectivity compared to the endogenous ligand (Cristalli and Volpini, 2003; Jacobson and Gao, 2006; Wilson and Mustafa, 2009; Ciruela, 2011).”
BackgroundByun, W. S., Kim, W. K., Yoon, J.-S., Jarhad, D. B., Jeong, L. S., & Lee, S. K. (2020) · Biomolecules · doi:10.3390/biom10040530 · Cited by 20
Salmaso, V., & Jacobson, K. A. (2020) · Biomolecules · doi:10.3390/biom10060812 · Cited by 20
Self-citationThe role of peripheral adenosine receptors in glutamate-induced pain nociceptive behavior
Macedo-Júnior, S. J., do Nascimento, F. P., Cerutti, M. L., & Santos, A. R. S. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09781-y · Cited by 20
“HEMADO has been shown to be selective to adenosine A3 receptors [30, 33, 38, 39].”
BackgroundChoi, W. J., Lee, H. W., Kim, H. O., Chinn, M., Gao, Z., Patel, A. R., Jacobson, K. A., Moon, H. R., Jung, Y. H., & Jeong, L. S. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.011 · Cited by 20
Self-citationSettimo, F. D., Primofiore, G., Taliani, S., Marini, A. M., Motta, C. L., Simorini, F., Salerno, S., Sergianni, V., Tuccinardi, T., Martinelli, A., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0708376 · Cited by 20
Caffeine therapy for apnoea of prematurity: Pharmacological treatment
Orozco-Gregorio, H., Mota‐Rojas, D., Villanueva, D. E., Bonilla‐Jaime, H., Suarez-Bonilla, X., Torres-González, L., Chavarría‐Bolaños, D., Gonzalez, R., Martínez-Rodríguez, R., & Ortega, M. E. T. (2011) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp.9000071 · Cited by 20
Moss, S. M., Jayasekara, P. S., Paoletta, S., Gao, Z., & Jacobson, K. A. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5002486 · Cited by 22
Self-citationAdenosine A1 antagonists and the cardiorenal syndrome
Gottlieb, S. S. (2008) · Current Heart Failure Reports · doi:10.1007/s11897-008-0017-x · Cited by 20
New Frontiers for the Treatment of Noncardiac Chest Pain: The Adenosine Receptors
Achem, S. R. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01102.x · Cited by 20
Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates
Klutz, A. M., Gao, Z., Lloyd, J., Shainberg, A., & Jacobson, K. A. (2008) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-6-12 · Cited by 20
“The A1 AR and A3 AR inhibit adenylyl cylase through the coupling of the Gi protein and are also involved in activating phospholipase C and potassium channels [5].”
BackgroundSelf-citationAgrawal, N., Chandrasekaran, B., & Al-Aboudi, A. F. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190306162006 · Cited by 19
Molecular probes for the human adenosine receptors
Yang, X., Heitman, L. H., IJzerman, A. P., & van der Es, D. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09753-8 · Cited by 19
“These receptors have been considered potential therapeutic targets in several disorders, including Parkinson’s disease, schizophrenia, analgesia, ischemia, and cancer [1].”
BackgroundMultisite Model of Allosterism for the Adenosine A1 Receptor
Deganutti, G., Barkan, K., Ladds, G., & Reynolds, C. A. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01331 · Cited by 18
Gliotransmission and adenosine signaling promote axon regeneration
Wang, F., Takle, K. A., Zhou, S., Qu, Y., Gong, J., Shang, Y., Wu, J., Liu, X., Diao, W., Li, Y., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.03.007 · Cited by 19
Plant-Derived Nutraceuticals Involved in Body Weight Control by Modulating Gene Expression
Vrânceanu, M., Hegheş, S. C., Cozma-Petruț, A. P., Banc, R., Stroia, C. M., Raischi, V., Miere, D., Popa, D., & Filip, L. A. (2023) · Plants · doi:10.3390/plants12122273 · Cited by 28
Yang, S.-C., Chiu, T., Yang, H., & Min, M. (2007) · Brain Research · doi:10.1016/j.brainres.2007.04.049 · Cited by 19
Fas-associated death domain protein and adenosine partnership: fad in RA
Vilmont, V., Tourneur, L., & Chiocchia, G. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/ker402 · Cited by 19
Azuaje, J., Jespers, W., Yaziji, V., Mallo‐Abreu, A., Majellaro, M., Caamaño, O., Loza, M. I., Cadavid, M. I., Brea, J. M., Åqvist, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00860 · Cited by 19
Federico, S., Margiotta, E., Salmaso, V., Pastorin, G., Kachler, S., Klotz, K., Moro, S., & Spalluto, G. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.042 · Cited by 19
“1 [1,2,4]Triazolo[1,5-c]pyrimidines as Adenosine Receptor Antagonists: Modifications at the 8”
BackgroundInfluentialLin, S. C. Y., Thorne, P. R., Housley, G. D., & Vlajkovic, S. M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00207 · Cited by 21
“adenosine A1R, based on its pharmacological profile (Jacobson and Gao, 2006).”
BackgroundAbdelrahman, A., Yerande, S. G., Namasivayam, V., Klapschinski, T. A., Alnouri, M. W., El‐Tayeb, A., & Müller, C. E. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111879 · Cited by 18
Reinecke, B. A., Wang, H., & Zhang, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191009164609 · Cited by 19
Adenosine receptors regulate exosome production
Ludwig, N., Azambuja, J. H., Rao, A., Gillespie, D. G., Jackson, E. K., & Whiteside, T. L. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09700-7 · Cited by 20
Design and in vivo activity of A3 adenosine receptor agonist prodrugs
Suresh, R. R., Jain, S., Chen, Z., Tosh, D. K., Ma, Y., Podszun, M. C., Rotman, Y., Salvemini, D., & Jacobson, K. A. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09715-0 · Cited by 22
“, its production as a consequence of elevated ATP inside and outside the cell is a protective feedback signal [1, 2].”
BackgroundSelf-citationDeciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor
Deganutti, G., Barkan, K., Preti, B., Leuenberger, M., Wall, M. J., Frenguelli, B. G., Lochner, M., Ladds, G., & Reynolds, C. A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00195 · Cited by 21
Almeida, I. D. A., Dorvigny, B. M., Tavares, L. S., Santana, L. N., & Lima‐Filho, J. V. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108090 · Cited by 19
Angelantonio, S. D., Piccioni, A., Moriconi, C., Trettel, F., Cristalli, G., Grassi, F., & Limatola, C. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.207282 · Cited by 23
Romagnoli, R., Baraldi, P. G., Carriòn, M. D., Lopez-Cara, L. C., Salvador, M. K., Preti, D., Tabrizi, M. A., Moorman, A. R., Vincenzi, F., Borea, P. A., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.002 · Cited by 19
Eastwood, P. R., González, J., Paredes, S., Nueda, A., Domènech, T., Alberti, J. J., & Vidal, B. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.045 · Cited by 19
Kovács, Z., Juhász, G. D., Dobolyi, Á., Bobest, M., Papp, V., Takáts, L., & Kékesi, K. A. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.10.010 · Cited by 26
Molecular Vibration-Activity Relationship in the Agonism of Adenosine Receptors
Chee, H. K., & Oh, S. J. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.282 · Cited by 19
“1) exerts its effects by interacting with AdoRs that are involved in various diseases, such as cardiac ischemia, arrhythmia, neurodegeneration, diabetes, glaucoma, and inflammation [5].”
BackgroundMethylxanthines and Ryanodine Receptor Channels
Guerreiro, S., Marien, M. R., & Michel, P. P. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_5 · Cited by 20
“Caffeine and its primary metabolite paraxanthine produced through liver enzymatic biotransformation were shown to exert protective effects for dopamine neurons in mouse models of Parkinson’s disease, but these effects were attributed to the antagonistic action of these compounds for A2A adenosine receptors (Xu et al.…”
BackgroundJeong, L. S., Lee, H. W., Kim, H. O., Tosh, D. K., Pal, S., Choi, W. J., Gao, Z., Patel, A. R., Williams, W. E., Jacobson, K. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.070 · Cited by 19
Self-citationKim, S. T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081024 · Cited by 18
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66–68].”
Doering, N. P., Taterra, M., Bermúdez, M., & Wolber, G. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01590 · Cited by 22
Glycogenolysis and Purinergic Signaling
Hertz, L., Xu, J., & Peng, L. (2014) · Advances in neurobiology · doi:10.1007/978-3-319-08894-5_3 · Cited by 19
Janowsky, A. J., Tosh, D. K., Eshleman, A. J., & Jacobson, K. A. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229666 · Cited by 19
“The dimethyl analog (compound 10) was initially intended for this purpose because it is known that disubstitution of the exocyclic amine of adenosine derivatives is generally not tolerated in AR binding (Jacobson and Gao, 2006).”
BackgroundSelf-citationWei, Y., Wang, M., Li, Y., Hong, Z., Li, D., & Lin, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111936 · Cited by 19
Nicotinonitrile as an essential scaffold in medicinal chemistry: an updated review (2015– present)
Hassan, H. A., Hisham, M., Osman, M., & Hayallah, A. M. (2022) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2022.162396.1166 · Cited by 18
Purinergic Tuning of the Tripartite Neuromuscular Synapse
Sousa-Soares, C., Noronha‐Matos, J. B., & Correia‐de‐Sá, P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03317-8 · Cited by 18
“It is noteworthy that these receptors may also couple to noncanonical pathways, thus regulating intracellular concentrations of Ca2+ and/or K+ through the activation of Gq proteincoupled mechanisms; others include a direct interference with ion currents across the plasma membrane via the βγ subunit of G proteins [63,…”
BackgroundMolecular mechanisms of nucleoside recycling in the brain
Ipata, P. L., Balestri, F., Camici, M., & Tozzi, M. G. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.10.007 · Cited by 18
Adenosine Amine Congener as a Cochlear Rescue Agent
Vlajkovic, S. M., Chang, H., Paek, S. Y., H.-T., H., Sreebhavan, S., Telang, R. S., Tingle, M. D., Housley, G. D., & Thorne, P. R. (2014) · BioMed Research International · doi:10.1155/2014/841489 · Cited by 18
“The peak cochlear level of ADAC detected following intravenous administration was consistent with pharmacological action, given the high affinity of A 1 receptors for ADAC [5].”
BackgroundKunduri, S., Dick, G. M., Nayeem, M. A., & Mustafa, S. J. (2013) · Physiological Reports · doi:10.1002/phy2.37 · Cited by 20
Squarcialupi, L., Falsini, M., Catarzi, D., Varano, F., Betti, M., Varani, K., Vincenzi, F., Ben, D. D., Lambertucci, C., Volpini, R., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.048 · Cited by 18
Protective Effect of Polydeoxyribonucleotide Against Renal Ischemia-Reperfusion Injury in Mice
Jeong, E.-M., Jang, H. J., Kim, S. S., Lee, S. Y., Oh, M. Y., Kim, H. J., Eom, D., Ham, J., & Han, D. J. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.01.028 · Cited by 18
“Adenosine modulates cellular and organ function by occupying 4 specific cell surface receptors (A1, A2A, A2B, and A3) [7].”
BackgroundLowe, P. T., Dall'Angelo, S., Mulder‐Krieger, T., IJzerman, A. P., Zanda, M., & O'Hagan, D. (2017) · ChemBioChem · doi:10.1002/cbic.201700382 · Cited by 19
Yadav, V., Teng, B., & Mustafa, S. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.024 · Cited by 19
“A1 and A3 AR activation cause vascular contraction, while A2A and A2B AR stimulation produces vascular relaxation (Hein et al., 2013; Jacobson and Gao, 2006; Mubagwa and Flameng, 2001; Mubagwa et al., 1996; Ohisalo, 1987; Olanrewaju and Mustafa, 2000; Olanrewaju et al., 2000).”
BackgroundHigh-Yielding Two-Step Synthesis of 6,8-Disubstituted N-9-Unprotected Purines
Ibrahim, N., & Legraverend, M. (2009) · Journal of Combinatorial Chemistry · doi:10.1021/cc900066v · Cited by 18
Choudhary, S. A., Bora, N., Banerjee, D., Arora, L., Das, A. S., Yadav, R., Klotz, K., Pal, D., Jha, A. N., & Dasgupta, S. (2019) · Biochemical Journal · doi:10.1042/bcj20190251 · Cited by 18
How Structural Biology Has Directly Impacted Our Understanding of P2X Receptor Function and Gating
Mansoor, S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2384-8_1 · Cited by 18
GPCR ligand–dendrimer (GLiDe) conjugates: future smart drugs?
Jacobson, K. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.002 · Cited by 18
“This need is especially evident for receptor classes such as the purine receptors, which encompasses both adenosine receptors (ARs) [3] and purinergic P2Y receptors [4] for extracellular nucleotides that are expressed at varying levels and in diverse combinations in nearly every organ.”
BackgroundSelf-citationYadav, R., Bansal, R., Kachler, S., & Klotz, K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.045 · Cited by 18
Hoffmann, K., Xifro, R. A., Hartweg, J. L., Spitzlei, P., Meis, K., Molderings, G. J., & von Kügelgen, I. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.003 · Cited by 18
Computational Study of the Binding Modes of Caffeine to the Adenosine A2AReceptor
Liu, Y., Burger, S. K., Ayers, P. W., & Vöhringer‐Martinez, E. (2011) · The Journal of Physical Chemistry B · doi:10.1021/jp2022049 · Cited by 18
Carlsson, J., Tosh, D. K., Phan, K., Gao, Z., & Jacobson, K. A. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300097g · Cited by 18
Self-citationMacedo-Júnior, S. J., do Nascimento, F. P., Cerutti, M. L., & Santos, A. R. S. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9327-2 · Cited by 17
“Furthermore, A2A receptor agonists can directly open K channels, promoting the hyperpolarization of the cell membrane and reduction of neuronal excitability, which are all involved in the inhibition of pain response [12, 13, 15, 16].”
Hatfield, S. M., Belikoff, B. G., Lukashev, D. E., Sitkovsky, M. V., & Ohta, A. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0908577 · Cited by 19
“The high-affinity A1R and low-affinity A3R are inhibitory G protein-coupled, and the A2Rs are subdivided into the high-affinity A2AR and low-affinity A2BR and are stimulatory G protein-coupled [22–25].”
BackgroundAhmed, R. G. (2018) · Toxicology Research · doi:10.1039/c8tx00227d · Cited by 19
Xanthine Derivatives in the Heart: Blessed or Cursed?
Szentmiklosi, A. J., Cseppentö, A., Gesztelyi, R., Zsuga, J., Körtvély, Á., Harmati, G., & Nánási, P. P. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796642391 · Cited by 23
“Therefore, the search for potent and subtype-selective adenosine receptor antagonists has been one of the most highly studied areas in medicinal chemistry [130, 193-198].”
BackgroundThermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour
Gessi, S., Fogli, E., Sacchetto, V., Varani, K., Merighi, S., Leung, E., Lennan, S. M., & Borea, P. A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.003 · Cited by 18
B‐Myb regulates the A2B adenosine receptor in vascular smooth muscle cells
Hilaire, C. S., Yang, D., Schreiber, B. M., & Ravid, K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21586 · Cited by 18
Ebersbach, H., & Geisse, S. (2012) · Biotechnology Journal · doi:10.1002/biot.201200066 · Cited by 22
“This receptor subfamily alone has been proposed as targets in treatments for ischemia, neurodegenerative disorders, cancer, and diabetes [5], among other conditions.”
Aronsson, P., Johnsson, M., Veselá, R., Winder, M., & Tobin, G. (2012) · Autonomic Neuroscience · doi:10.1016/j.autneu.2012.10.006 · Cited by 17
“The ARs are known to modulate tissue damage and inflammation (for reviews see: (Fredholm, 2007; Jacobson and Gao, 2006)), as well as having direct ogy, University of Gothenburg, 6 34 40; fax: +46 31 786 31 64. nsson). rights reserved. effects on detrusor function (Hills et al., 1984; Aronsson et…”
Cardioprotective role of APIP in myocardial infarction through ADORA2B
Lim, B., Jung, K., Gwon, Y., Oh, J. G., Roh, J.-I., Hong, S.-H., Kho, C., Park, W.-J., Lee, H., Bae, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1746-3 · Cited by 19
Goßen, J., Ribeiro, R. P., Bier, D. D., Neumaier, B., Carloni, P., Giorgetti, A., & Rossetti, G. (2023) · Chemical Science · doi:10.1039/d3sc02352d · Cited by 17
Federico, S., Ciancetta, A., Sabbadin, D., Paoletta, S., Pastorin, G., Cacciari, B., Klotz, K., Moro, S., & Spalluto, G. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300899q · Cited by 17
Yadav, V., Hong, K. L., Zeldin, D. C., & Nayeem, M. A. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2821-z · Cited by 17
A1 Adenosine Receptor Agonists, Antagonists, and Allosteric Modulators
Gao, Z., Tosh, D. K., Jain, S., Yu, J., Suresh, R. R., & Jacobson, K. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90808-3_4 · Cited by 21
Self-citationMartínez‐Archundia, M., Correa‐Basurto, J., Montaño, S., & Rosas‐Trigueros, J. L. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1564700 · Cited by 18
“For these reasons, A2A receptors are considered important targets to treat neurological diseases (Jacobson & Gao, 2006).”
BackgroundRetrospective Ensemble Docking of Allosteric Modulators in an Adenosine G-Protein-Coupled Receptor
Bhattarai, A., Wang, J., & Miao, Y. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129615 · Cited by 19
Reduction of prefrontal purinergic signaling is necessary for the analgesic effect of morphine
Zeng, Y., Luo, H., Gao, Z., Zhu, X., Shen, Y., Li, Y., Hu, J., & Yang, J. (2021) · iScience · doi:10.1016/j.isci.2021.102213 · Cited by 18
Self-citationCathenaut, L., Leonardon, B., Kuster, R., Inquimbert, P., Schlichter, R., & Hugel, S. (2021) · Pain · doi:10.1097/j.pain.0000000000002460 · Cited by 21
Adenosine A2A receptor as a drug target for treatment of sepsis
Сивак, К. В., Vasin, A. V., Egorov, V. V., Tsevtkov, V. B., Kuzmich, N. N., Savina, V. A., & Киселев, О. И. (2016) · Molecular Biology · doi:10.1134/s0026893316020230 · Cited by 17
Mangmool, S., Kyaw, E. T. H., Nuamnaichati, N., Pandey, S., & Parichatikanond, W. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116175 · Cited by 19
Dewaeles, E., Carvalho, K., Fellah, S., Sim, J., Boukrout, N., Caillierez, R., Ramakrishnan, H., der Hauwaert, C. V., Shankara, J. V., Martin, N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152924 · Cited by 23
“Its physiological function relies on 4 GPCRs: A 1 , A 2A , A 2B , and A 3 (17–20).”
BackgroundEffects of Adenosine on Lymphangiogenesis
Lenoir, B., Wagner, D. R., Blacher, S., Sala‐Newby, G. B., Newby, A. C., Noël, A., & Devaux, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092715 · Cited by 19
“Thus, adenosine receptors are appealing therapeutic targets [23].”
BackgroundObstacles to effective Toll-like receptor agonist therapy for hematologic malignancies
Spaner, D., Foley, R., Galipeau, J., & Bramson, J. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210905 · Cited by 18
“A number of specific adenosine-receptor antagonists are in clinical development (Jacobson and Gao, 2006) and may be useful adjuncts to TLR agonists in hematologic cancer patients.”
BackgroundVascular Adenosine Receptors; Potential Clinical Applications
Ho, M., & Rose’Meyer, R. B. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111311030007 · Cited by 17
Wang, W., Huang, Q., Zou, J., Li, L., & Yang, S. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12470 · Cited by 17
“Targets involved in the test include HSP90, PLK1, JAK3, c-Met, CXCR4, b 1AR, b 2AR, AR, HIV IN, HMGCR, PARP, PTP1B, A2AAR, and YopH.”
BackgroundEfficient Radiosynthesis of 2-[18F]Fluoroadenosine: A New Route to 2-[18F]Fluoropurine Nucleosides
Marchand, P., Lorilleux, C., Gilbert, G., Gourand, F., Sobrio, F., Peyronnet, D., Dhilly, M., & Barré, L. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100055m · Cited by 17
Adenosine amine congener ameliorates cisplatin-induced hearing loss
Gunewardene, N. (2013) · World Journal of Otorhinolaryngology · doi:10.5319/wjo.v3.i3.100 · Cited by 17
Li, Z., Chakraborty, S., & Xu, G. (2016) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x16014278 · Cited by 17
Xu, X., Zheng, S., Xiong, Y., Wang, X., Qin, W., Zhang, H., & Sun, B. (2017) · Inflammation Research · doi:10.1007/s00011-016-1021-3 · Cited by 17
“Second, extracellular ADO generates a range of tissue responses that can generally be viewed as organ protective, thereby mediating homeostasis [19], which falls into four categories: increasing the ratio of oxygen supply to demand; protecting against ischemic damage by cell conditioning; triggering anti-inflammatory…”
BackgroundNamvar, S., Fathollahi, Y., Javan, M., Zeraati, M., Mohammad‐Zadeh, M., Shojaei, A., & Mirnajafi‐Zadeh, J. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.02.047 · Cited by 17
Do, T., Sun, Q., Beuve, A. V., & Kuzhikandathil, E. V. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04388.x · Cited by 17
Singer, P., Wei, C. J., Chen, J., Boison, D., & Yee, B. K. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.024 · Cited by 18
Molecular Basis of Modulating Adenosine Receptors Activities
Al-Qattan, M. N. M., & Mordi, M. N. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190304122624 · Cited by 18
Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors
Samanta, P. N., Kar, S., & Leszczyński, J. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190304123545 · Cited by 16
Renault, P., Louet, M., Marie, J., Labesse, G., & Floquet, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-41980-x · Cited by 18
Nkomba, G., Terre’Blanche, G., van Rensburg, H. D. J., & Legoabe, L. J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02908-9 · Cited by 16
“4 Structure-activity relationships of amino-3,5dicyanopyridines (6a, 6f, 6g) vs thieno[2,3]pyridines (7a, 7c, 7d)”
BackgroundInfluentialTRPA1, TRPV1, and Caffeine: Pain and Analgesia
Puthumana, E. A., Muhamad, L., Young, L. A., & Chu, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147903 · Cited by 18
“Caffeine has primarily been studied for its pain-relieving effects through the competitive inhibition of adenosine receptors (ARs), particularly A1, A2a, and A2b subtypes [81–83].”
BackgroundTherapeutic potential of A2and A3adenosine receptor: a review of novel patented ligands
Federico, S., & Spalluto, G. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.669375 · Cited by 16
de Souza, L. F., Jardim, F. R., Sauter, I. P., de Souza, M. M., Barreto, F., Margis, R., & Bernard, E. A. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.09.012 · Cited by 16
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.